Beyond Achondroplasia

Growing together with Clara

June 25, 2017
by inesp.alves
3 Comments

Therachon heading to Phase 1 clinical trial

Therachon’s medicine in development for achondroplasia, TA-46, was granted Orphan Drug designation by the medicine agencies FDA and EMA. TA-46 is a type 3 fibroblast growth factor receptor antagonist addressing achondroplasia. This medicine is an inactive form of the receptor that … Continue reading

May 14, 2017
by inesp.alves
3 Comments

BioCentury published the article “Competing for growth”

BioCentury´s Senior writer Mike Leviten wrote a substantial article about the current medicines in research and development for achondroplasia. The article was published on the 7th April. This competition between pharma companies is very positive since it stimulates industry to … Continue reading

January 5, 2017
by inesp.alves
5 Comments

Therachon protein for achondroplasia: TA-46

A press release from Business Wire stated that Therachon AG, a biotechnology company focused on rare genetic diseases, announced today it has appointed Luca Santarelli, M.D., as Chief Executive Officer and Director, and raised more $5 million for new medicines R&D (research a … Continue reading

October 1, 2015
by inesp.alves
0 comments

Soluble FGFR3 going forward with Therachon

Soluble FGFR3 was first mentioned here in September 2013. This protein is able to restore growth by acting has a decoy receptor and prevents FGFs from binding to mutant FGFR3 and was able to increase bone length and reduce complications associated with achondroplasia in transgenic … Continue reading

Translate »